Multiple Media Outlets Highlight FDA Approval of the BASHIR™ Endovascular Catheter for Treatment of Acute Pulmonary Embolism

Multiple media outlets, including the Philadelphia Business Journal, Healio Cardiac/Vascular Intervention and BioBuzz, highlighted the news that the BASHIR™ Endovascular Catheter (THROMBOLEX, Inc.), invented at the Lewis Katz School of Medicine at Temple University and developed by Thrombolex Inc., has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of acute pulmonary embolism. The approval is based on data from the RESCUE study, a National Institutes of Health-sponsored multicenter clinical trial in which treatment with the BASHIR™ Endovascular Catheter led to rapid and marked improvement in lung artery blockages, resulting in improved heart function in patients with pulmonary embolism. Riyaz Bashir, MD, FACC, Professor of Medicine at the Katz School of Medicine and Director of Vascular and Endovascular Medicine at Temple University Hospital, is co-inventor of the BASHIR™ Endovascular Catheter. The Philadelphia Inquirer interviewed Dr. Bashir for their article.